Position in ARVN
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$709,966
-$1,053,663 QoQ
Shares Held
66,978
-55.0% QoQ
Ownership
0.102%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ZACKS INVESTMENT MANAGEMENT holds $33,185,332 across 8 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
55,052 | $27,345,979 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
32,627 | $2,553,715 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
8,417 | $2,533,769 | |
| 4 | AUPH |
Aurinia Pharmaceuticals Inc.
|
36,687 | $622,578 | |
| 5 | LCTX |
Lineage Cell Therapeutics, Inc.
|
42,084 | $55,130 | |
| 6 | AGEN |
Agenus Inc
|
10,550 | $32,283 | |
| 7 | INO |
Inovio Pharmaceuticals, Inc.
|
26,435 | $29,078 | |
| 8 | GERN |
Geron Corp
|
10,000 | $12,800 |
All Filings in ARVN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $709,966 | 66,978 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,763,629 | 148,704 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,346,841 | 158,080 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $668,722 | 90,859 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $644,372 | 91,791 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,657,208 | 86,448 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $2,212,439 | 89,827 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,177,462 | 81,798 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $3,129,890 | 75,821 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $2,950,966 | 71,695 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||